{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:30:07Z","timestamp":1773797407730,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Instituto de Salud Carlos III, Ministerio de Econom\u00eda y Competitividad","award":["PI16\/094 and PI20\/00867"],"award-info":[{"award-number":["PI16\/094 and PI20\/00867"]}]},{"DOI":"10.13039\/501100019945","name":"Direcci\u00f3 General de Recerca, Generalitat de Catalunya","doi-asserted-by":"crossref","award":["AGAUR 2014-SGR-383, 2017-SGR-999."],"award-info":[{"award-number":["AGAUR 2014-SGR-383, 2017-SGR-999."]}],"id":[{"id":"10.13039\/501100019945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"DOI":"10.1186\/s13000-025-01655-w","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T06:41:36Z","timestamp":1745995296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases"],"prefix":"10.1186","volume":"20","author":[{"given":"Laura","family":"Gonz\u00e1lez-Guerrero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Castellet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Guijarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Lloveras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Pratcorona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignasi","family":"Gich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pau","family":"Berenguer-Molins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00falia","family":"Perera-Bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lurdes","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00ed","family":"Mascar\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Sampol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Garcia-Gui\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Vives","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Tormo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Arnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neus","family":"Villamor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep F.","family":"Nomded\u00e9u","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"12","key":"1655_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"key":"1655_CR2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.pathol.2021.02.001","volume":"53","author":"TI George","year":"2021","unstructured":"George TI, Bajel A. Diagnosis of rare subtypes of acute myeloid leukaemia and related neoplasms. Pathology. 2021;53:312\u201327. https:\/\/doi.org\/10.1016\/j.pathol.2021.02.001.","journal-title":"Pathology"},{"key":"1655_CR3","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","volume":"129","author":"D Thomas","year":"2017","unstructured":"Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. 2017;129:1577\u201385. https:\/\/doi.org\/10.1182\/blood-2016-10-696054.","journal-title":"Blood"},{"key":"1655_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s12185-017-2221-5","volume":"105","author":"D Hanekamp","year":"2017","unstructured":"Hanekamp D, Cloos J, Schuurhuis GJ. Leukemic stem cells: identification and clinical application. Int J Hematol. 2017;105:549\u201357. https:\/\/doi.org\/10.1007\/s12185-017-2221-5.","journal-title":"Int J Hematol"},{"key":"1655_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/cyto.b.21080","volume":"84 B","author":"CG Roth","year":"2013","unstructured":"Roth CG, Garner K, Eyck S, Ten, et al. TIM3 expression by leukemic and non-leukemic myeloblasts. Cytom Part B - Clin Cytom. 2013;84 B:167\u201372. https:\/\/doi.org\/10.1002\/cyto.b.21080.","journal-title":"Cytom Part B - Clin Cytom"},{"key":"1655_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","volume":"17","author":"Y Kikushige","year":"2015","unstructured":"Kikushige Y, Miyamoto T, Yuda J, et al. A TIM-3\/Gal-9 autocrine stimulatory loop drives Self-Renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell. 2015;17:341\u201352. https:\/\/doi.org\/10.1016\/j.stem.2015.07.011.","journal-title":"Cell Stem Cell"},{"key":"1655_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ebiom.2017.07.018","volume":"22","author":"I Gon\u00e7alves Silva","year":"2017","unstructured":"Gon\u00e7alves Silva I, Yasinska IM, Sakhnevych SS, et al. The Tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine. 2017;22:44\u201357. https:\/\/doi.org\/10.1016\/j.ebiom.2017.07.018.","journal-title":"EBioMedicine"},{"key":"1655_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0611-3","volume":"7","author":"P Dama","year":"2019","unstructured":"Dama P, Tang M, Fulton N, et al. Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019;7:1\u20137. https:\/\/doi.org\/10.1186\/s40425-019-0611-3.","journal-title":"J Immunother Cancer"},{"key":"1655_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3233\/CBM-181368","volume":"22","author":"AM Zahran","year":"2018","unstructured":"Zahran AM, Mohammed Saleh MF, Sayed MM, et al. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia. Cancer Biomarkers. 2018;22:587\u201395. https:\/\/doi.org\/10.3233\/CBM-181368.","journal-title":"Cancer Biomarkers"},{"key":"1655_CR10","unstructured":"CD200 Gene. - GeneCards| OX2G Protein| OX2G Antibody. https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=CD200#protein_expression. Accessed 17 Feb 2021."},{"key":"1655_CR11","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.4049\/jimmunol.171.6.3034","volume":"171","author":"GJ Wright","year":"2003","unstructured":"Wright GJ, Cherwinski H, Foster-Cuevas M, et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol. 2003;171:3034\u201346. https:\/\/doi.org\/10.4049\/jimmunol.171.6.3034.","journal-title":"J Immunol"},{"issue":"6","key":"1655_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/s1471-4906(02)02223-8","volume":"23","author":"AN Barclay","year":"2002","unstructured":"Barclay AN, Wright GJ, Brooke G, et al. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 2002;23(6):285\u201390. https:\/\/doi.org\/10.1016\/s1471-4906(02)02223-8.","journal-title":"Trends Immunol"},{"key":"1655_CR13","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/leu.2012.75","volume":"26","author":"SJ Coles","year":"2012","unstructured":"Coles SJ, Hills RK, Wang ECY, et al. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3 \u00de regulatory T cells. Leukemia. 2012;26:2146\u20138. https:\/\/doi.org\/10.1038\/leu.2012.75.","journal-title":"Leukemia"},{"key":"1655_CR14","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.1182\/bloodadvances.2020001802","volume":"4","author":"JM Ho","year":"2020","unstructured":"Ho JM, Dobson SM, Voisin V, et al. CD200 expression marks leukemia stem cells in human AML. Blood Adv. 2020;4:5402\u201313. https:\/\/doi.org\/10.1182\/bloodadvances.2020001802.","journal-title":"Blood Adv"},{"key":"1655_CR15","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/leu.2012.77","volume":"26","author":"SJ Coles","year":"2012","unstructured":"Coles SJ, Hills RK, Wang ECY, et al. Expression of CD200 on AML blasts directly suppresses memory T-cell function. Leukemia. 2012;26:2148\u201351. https:\/\/doi.org\/10.1038\/leu.2012.77.","journal-title":"Leukemia"},{"key":"1655_CR16","doi-asserted-by":"publisher","first-page":"30212","DOI":"10.18632\/oncotarget.4901","volume":"6","author":"D Damiani","year":"2015","unstructured":"Damiani D, Tiribelli M, Raspadori D, et al. Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors. Oncotarget. 2015;6:30212\u201321. https:\/\/doi.org\/10.18632\/oncotarget.4901.","journal-title":"Oncotarget"},{"key":"1655_CR17","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/leu.2011.1","volume":"25","author":"SJ Coles","year":"2011","unstructured":"Coles SJ, Wang ECY, Man S, et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia. 2011;25:792\u20139. https:\/\/doi.org\/10.1038\/leu.2011.1.","journal-title":"Leukemia"},{"key":"1655_CR18","first-page":"297","volume":"11","author":"C Ngwa","year":"2019","unstructured":"Ngwa C, Liu F. CD200-CD200R signaling and diseases: a potential therapeutic target? Int J Physiol Pathophysiol Pharmacol. 2019;11:297\u2013309.","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"1655_CR19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0145-2126(98)00185-4","volume":"23","author":"JF Nomded\u00e9u","year":"1999","unstructured":"Nomded\u00e9u JF, Mateu R, Alt\u00e8s A, et al. Enhanced myeloid specificity of CD 117 compared with CD13 and CD33. Leuk Res. 1999;23:341\u20137. https:\/\/doi.org\/10.1016\/S0145-2126(98)00185-4.","journal-title":"Leuk Res"},{"key":"1655_CR20","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1158\/0008-5472.CAN-12-1390","volume":"72","author":"KK Wong","year":"2012","unstructured":"Wong KK, Brenneman F, Chesney A, et al. Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice. Cancer Res. 2012;72:4931\u201343. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1390.","journal-title":"Cancer Res"},{"key":"1655_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/cyto.b.21722","volume":"96","author":"A Mora","year":"2019","unstructured":"Mora A, Bosch R, Cuellar C, et al. CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia. Cytom Part B - Clin Cytom. 2019;96:143\u20138. https:\/\/doi.org\/10.1002\/cyto.b.21722.","journal-title":"Cytom Part B - Clin Cytom"},{"key":"1655_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"issue":"11","key":"1655_CR23","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/blood-2010-10-314682","volume":"17","author":"E Matutes","year":"2011","unstructured":"Matutes E, Pickl WF, Van\u2019t Veer M, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood. 2011;17(11):3163\u201371. https:\/\/doi.org\/10.1182\/blood-2010-10-314682.","journal-title":"Blood"},{"issue":"1","key":"1655_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger, et al. STAR: ultrafast universal RNA-seq aligner. Bioinf (Oxford England). 2013;29(1):15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635.","journal-title":"Bioinf (Oxford England)"},{"key":"1655_CR25","doi-asserted-by":"publisher","unstructured":"Yang Liao GK, Smyth W, Shi. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 2019;47(8):e47. https:\/\/doi.org\/10.1093\/nar\/gkz114","DOI":"10.1093\/nar\/gkz114"},{"issue":"5","key":"1655_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095.","journal-title":"Cancer Discov"},{"issue":"269","key":"1655_CR27","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. https:\/\/doi.org\/10.1126\/scisignal.2004088.","journal-title":"Sci Signal"},{"key":"1655_CR28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-0816","author":"I De Bruijn","year":"2023","unstructured":"De Bruijn I, Kundra R, Mastrogiacomo B, et al. Cancer Res. 2023;83(23):3861\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0816. Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal."},{"issue":"8","key":"1655_CR29","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40(8):850\u2013e8649. https:\/\/doi.org\/10.1016\/j.ccell.2022.07.002.","journal-title":"Cancer Cell"},{"key":"1655_CR30","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath SWGCNA. An R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559. https:\/\/doi.org\/10.1186\/1471-2105-9-559.","journal-title":"BMC Bioinformatics"},{"issue":"19","key":"1655_CR31","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1182\/blood-2009-08-238899","volume":"116","author":"MP Martelli","year":"2010","unstructured":"Martelli MP, Pettirossi V, Thiede, et al. CD34\u2009+\u2009cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood. 2010;116(19):3907\u201322. https:\/\/doi.org\/10.1182\/blood-2009-08-238899.","journal-title":"Blood"},{"key":"1655_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/ejh.12915","volume":"99","author":"M Tiribelli","year":"2017","unstructured":"Tiribelli M, Geromin A, Cavallin M, et al. ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML. Eur J Haematol. 2017;99:269\u201374. https:\/\/doi.org\/10.1111\/ejh.12915.","journal-title":"Eur J Haematol"},{"key":"1655_CR33","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/sj.leu.2404559","volume":"21","author":"A Tonks","year":"2007","unstructured":"Tonks A, Hills R, White P, Rosie B, Mills KI, RD. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia. 2007;21:566\u20138. https:\/\/doi.org\/10.1038\/sj.leu.2404559.","journal-title":"Leukemia"},{"key":"1655_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.98561","volume":"3","author":"E Coustan-Smith","year":"2018","unstructured":"Coustan-Smith E, Song G, Shurtleff S, et al. Universal monitoring of minimal residual disease in acute myeloid leukemia. JCI Insight. 2018;3:1\u201314. https:\/\/doi.org\/10.1172\/jci.insight.98561.","journal-title":"JCI Insight"},{"key":"1655_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/ejh.12130","volume":"91","author":"M Hoyos","year":"2013","unstructured":"Hoyos M, Nomdedeu JF, Esteve J, et al. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings and minimal residual disease. Eur J Haematol. 2013;91:209\u201318. https:\/\/doi.org\/10.1111\/ejh.12130.","journal-title":"Eur J Haematol"},{"key":"1655_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-9-165","volume":"9","author":"G Dentesano","year":"2012","unstructured":"Dentesano G, Straccia M, Ejarque-Ortiz A, et al. Inhibition of CD200R1 expression by C\/EBP beta in reactive microglial cells. J Neuroinflammation. 2012;9:1\u201313. https:\/\/doi.org\/10.1186\/1742-2094-9-165.","journal-title":"J Neuroinflammation"},{"key":"1655_CR37","doi-asserted-by":"publisher","unstructured":"Papaemmanuil E, Ph D, Gerstung M et al. (2016) Europe PMC funders group genomic classification and prognosis in acute myeloid leukemia. 374:2209\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1516192.Genomic","DOI":"10.1056\/NEJMoa1516192.Genomic"},{"key":"1655_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.leukres.2010.05.015","volume":"35","author":"J Nomdedeu","year":"2011","unstructured":"Nomdedeu J, Bussaglia E, Villamor N, et al. Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size. Leuk Res. 2011;35:163\u20138. https:\/\/doi.org\/10.1016\/j.leukres.2010.05.015.","journal-title":"Leuk Res"},{"key":"1655_CR39","doi-asserted-by":"publisher","unstructured":"Taussig DC, Vargaftig J, Miraki-moud F et al. (2016) Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34 \u03ea fraction. 115:1976\u201385. https:\/\/doi.org\/10.1182\/blood-2009-02-206565.The","DOI":"10.1182\/blood-2009-02-206565.The"},{"issue":"3","key":"1655_CR40","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMoa041974","volume":"352","author":"M Alcalay","year":"2005","unstructured":"Alcalay M, Ph D, Rosati R, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254\u201366. https:\/\/doi.org\/10.1056\/NEJMoa041974.","journal-title":"N Engl J Med"},{"key":"1655_CR41","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312. https:\/\/doi.org\/10.1038\/s41375-018-0357-9.","journal-title":"Leukemia"},{"key":"1655_CR42","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","volume":"121","author":"M Pratcorona","year":"2013","unstructured":"Pratcorona M, Brunet S, Nomded\u00e9u J, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood. 2013;121:2734\u20138. https:\/\/doi.org\/10.1182\/blood-2012-06-431122.","journal-title":"Blood"},{"key":"1655_CR43","doi-asserted-by":"publisher","unstructured":"Nip C, Wang L, Liu C. CD200\/CD200R: bidirectional role in Cancer progression and immunotherapy. Biomedicines. 2023;11. https:\/\/doi.org\/10.3390\/biomedicines11123326.","DOI":"10.3390\/biomedicines11123326"},{"key":"1655_CR44","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1182\/blood-2017-04-777052","volume":"130","author":"SK Oda","year":"2017","unstructured":"Oda SK, Daman AW, Garcia NM, Wagener F, Schmitt TM, Tan X, Chapuis AG, Greenberg PD. A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia. Blood. 2017;130:2410\u20139. https:\/\/doi.org\/10.1182\/blood-2017-04-777052.","journal-title":"Blood"},{"key":"1655_CR45","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jare.2019.05.006","volume":"20","author":"\u00c1 Nagy","year":"2019","unstructured":"Nagy \u00c1, \u0150sz \u00c1, Budczies J, et al. Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival. J Adv Res. 2019;20:105\u201316. https:\/\/doi.org\/10.1016\/j.jare.2019.05.006.","journal-title":"J Adv Res"},{"key":"1655_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/bjh.17125","volume":"193","author":"N Rastogi","year":"2021","unstructured":"Rastogi N, Baker S, Man S, et al. Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo. Br J Haematol. 2021;193:155\u20139. https:\/\/doi.org\/10.1111\/bjh.17125.","journal-title":"Br J Haematol"},{"key":"1655_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0710-1","volume":"7","author":"D Mahadevan","year":"2019","unstructured":"Mahadevan D, Lanasa MC, Farber C, et al. Phase i study of Samalizumab in chronic lymphocytic leukemia and multiple myeloma: Blockade of the immune checkpoint CD200. J Immunother Cancer. 2019;7:1\u201313. https:\/\/doi.org\/10.1186\/s40425-019-0710-1.","journal-title":"J Immunother Cancer"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01655-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-025-01655-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01655-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T06:41:38Z","timestamp":1745995298000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-025-01655-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1655"],"URL":"https:\/\/doi.org\/10.1186\/s13000-025-01655-w","relation":{"references":[{"id-type":"doi","id":"10.1158\/0008-5472.CAN-23-0816","asserted-by":"subject"}]},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the CEIC (Ethical Committee number IIBSP-LEU-2021-120).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors consent to the publication of this document.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}